Vyome (HIND) Q3 2025 earnings summary

Executive summary

• Completed first full reporting period as a public company, finalizing a streamlined NASDAQ listing with a 100% common stock structure.

• Strengthened leadership with key hires in technology and clinical development, both with Big Pharma experience.

• Advanced lead program VT-1953 for malignant fungating wounds, showing statistically significant Phase 2 interim results.

• Acquired MIT startup Oculo to launch an AI strategy and initiated an AI-focused healthcare initiative.

• Focused on immuno-inflammatory conditions, leveraging US-India innovation corridors for cost-efficient development.

Financial highlights

• Ended Q3 2025 with $5.7 million in cash, cash equivalents, and short-term investments, providing runway through 2026.

• Net loss of $9.2 million for the nine months ended September 30, 2025, primarily due to one-time merger and financing-related expenses.

• Revenues of $283,163 for the nine months ended September 30, 2025, up from $195,516 year-over-year.

• Operating expenses increased to $7.7 million from $882,543 year-over-year.

• Lower than anticipated cash burn due to disciplined, cost-efficient operations.

Outlook and guidance

• Cash runway expected to extend through 2026, supporting planned clinical activities.

• Full Phase 2 data for VT-1953 expected in December 2025; FDA discussions and orphan drug designation planned for the first half of 2026.

• Regulatory engagement for VT-1908 planned for the first half of 2026.